Showing 1 - 9 of 9
Persistent link: https://www.econbiz.de/10012082424
ABSTRACT This study exploits a natural experiment in the province of Ontario, Canada, to identify the impact of pay‐for‐performance (P4P) incentives on the provision of targeted primary care services and whether physicians' responses differ by age, size of patient population, and baseline...
Persistent link: https://www.econbiz.de/10011005327
Persistent link: https://www.econbiz.de/10011005343
Persistent link: https://www.econbiz.de/10010545862
This study examines the impact that private financing of prescription drugs in Canada has on equity in the utilization of publicly financed physician services. The complementary nature of prescription drugs and physician service use alongside the reliance on private finance for drugs may induce...
Persistent link: https://www.econbiz.de/10008542730
The price elasticity of demand for prescription drugs is a crucial parameter of interest in designing pharmaceutical benefit plans. Estimating the elasticity using micro-data, however, is challenging because insurance coverage that includes deductibles, co-insurance provisions and maximum...
Persistent link: https://www.econbiz.de/10005689839
This paper presents the findings from simulations of the introduction of publicly funded medical savings accounts (MSAs) in the province of Ontario, Canada. The analysis exploits a unique data set linking population-based health survey information with individual-level information on all...
Persistent link: https://www.econbiz.de/10005689871
This paper employs a cohort analysis to examine the relative importance of different factors in explaining changes in the number of hours spent in direct patient care by Canadian general|family practitioners (GPs) over the period 1982-2003. Cohorts are defined by year of graduation from medical...
Persistent link: https://www.econbiz.de/10005442782
In May, 2003, British Columbia transitioned from an age-based public drug program, with public subsidy primarily based on age, to an age-irrelevant income-based drug program, in which public subsidy is based primarily on household income. As one of the specific aims of the policy change was to...
Persistent link: https://www.econbiz.de/10005694056